Search

The article presents a case study of a 71-year-old woman with stromal adenosarcoma of the uterus. She was suffering from a heavy postmenopausal bleeding though she did not have any significant past medical history and is not under any medication. Due to the inverted uterus being found, she under went radical hysterectomy and bilateral salpingo-oophorectomy approach. She made an excellent postoperative recovery with no recommended chemotherapy.

The Advanced Photon Source planned for construction at Argonne National Laboratory is based on a low-emittance storage-ring operated at 7 GeV and capable of providing tunable undulator radiation from 4 to 40 keV ( using the first and the third harmonics). A technical description of the accelerator facility and the storage ring is presented in this overview, along with a brief summary of the characteristics of radiation that will be available from the insertion devices. Various plans for user access to this national user facility are also given. [ABSTRACT FROM AUTHOR]

The article considers the role of vaginal microbiome in the aetiology of gynecological cancers. Topics discussed are factors that influence the acquisition of genital human papillomavirus (HPV) that are important in the pathogenesis of cervical cancer, efficacy of hysterectomy or salpingectomy with ovarian conservation and tubal ligation in reducing the risk of ovarian cancer, and role of vaginal microbiome in endometrial carcinogenesis.

It is indeed plausible that women with certain vaginal microbiome CST groups are more prone to acquiring and failing to clear high-risk HPV and therefore identifying these CSTs is important to (1) predict cervical cancer risk, (2) develop targeted prevention strategies, and (3) test novel therapeutic strategies based on pre/probiotics. Well-designed longitudinal studies with adequate sample sizes, and using standardised sampling and analytical methods are now needed to provide robust evidence on what CST subtypes are linked with high-risk HPV and cervical cancer and importantly, to confirm causality. FundingKN is supported by a Cancer Research UK Manchester Cancer Research Centre Clinical Research Fellowship. [Extracted from the article]

The article focuses on extension of BRCA1/2 germline testing to all high-grade serous ovarian cancer (HGSOC) regardless of family history. It mentions benefits of poly ADP ribose polymerase inhibitor (PARPi) therapies and no endometrioid types were recorded and identify somatic mutations that would otherwise go undetected but may determine sensitivity to PARPi. It also mentions affected women would then only require germline testing if a pathogenic variant were identified in tumour material.

The article discusses the article by M. Zakhour and colleagues about women with atypical endometrial hyperplasia (AEH) or endometrial cancer (EC) who were treated with progestins. Topics include the use of immunohistochemistry to define lesions as mismatch repair (MMR)-competent or MMR-deficient, the senescence, differentiation, and apoptosis induced by progestin, and the response rate to intrauterine progestins.

Despite the success of cervical screening, cancer of the cervix is the fourth most common cancer affecting women worldwide (CRUK 2014). Rates are particularly high in developing nations, which lack the requisite infrastructure for cytology and colposcopy-based screening, and in certain demographic groups, where uptake of screening is poor. Recent research has focussed on developing less invasive and potentially more acceptable means of identifying women at high risk of cervical intraepithelial neoplasia (CIN). Urinary HPV testing has received particular attention because of the ease of obtaining samples and the opportunity this affords to overcoming barriers to cervical screening like embarrassment and discomfort. This article is protected by copyright. All rights reserved. [ABSTRACT FROM AUTHOR]